Discovery
By utilizing cutting-edge technologies and innovative approaches with a goal to deliver tailored solutions, our experienced, dedicated development experts help you expedite development journey.
The choice for your next dual-specificity therapeutics
-
The choice for your
next dual-specificity
therapeutics - S-DUAL™ is an advanced, high-yield bispecific antibody platform designed to meet your needs and generate perfect pairing every time. The innovative dual-specificity of bispecific antibodies opens up a wide range of applications, enabling clients to reach commercialization much more efficiently.
- Asymmetrical Structure
-
- Clear separation of initial impurities
- Easy in-process control during manufacturing
- Low Immunogenicity Risk
-
- Similar structure to typical bispecific antibodies
- Antibody-derived protein only
- Correctly Paired bsAb
-
- Knob-into-Hole CH3 dimer applied on an additional domain in one Fab arm
- >95% purity
- Streamlined Access
-
- Favorable contract terms with competitive pricing
- Only Parental antibody sequences needed to develop BsAb
Click for more information
Late Discovery
- 1 Month (including vector construction)
-
S-DUALTM
Proprietary Bispecific Antibody Platform
- Asymmetric IgC-like structure
- Low immunogenicity risk
- Correct HC & LC pairing
- Streamlined Access
- 1 Month Small scale Ab production
-
Small scale Ab production
- Small scale Ab production with transient expression
- Additional material can be produced for supplemental studies
- 1 Month Developability Assessment
-
DEVELOPICKTM
Developability assessment
- Thermo-stability
- Aggregation
- Purity Profile
- Concentration
IND / BLA Approval
Time & cost for drug developmentoptimized with DEVELOPICKTM
Ensure success from an early stage
- Timely Evaluation
-
- Receives results in just 1 month
- Efficient Assessment
-
- Requires 20mg of material only
- Systematic Scoring System
-
- Guides you to the optimal decision
Our proprietary platform ensures your path to development success by implementing systematic approach to predict candidates with the best potential for advancement.
DEVELOPICK ™
- Small scale Ab production
-
1 Month Small scale Ab production
- Asymmetric IgC-like structure
- Low immunogenicity risk
- Correct HC & LC pairing
- Streamlined Access
- DEVELOPICK ™ Developability assessment
-
1 Month Developability Assessment
- Thermo-stability
- Aggregation
- Purity Profile
- Concentration
- Cell line development to Commercialization
-
Time & cost for drug development optimized with DEVELOPICKTM
- Use of S-CHOice® cell line for a stable cell line development
IND / BLA Approval
Accelerate your journey with
Knowing the right candidate with the highest possibility for success is critical for continuing your journey to IND, BLA, and beyond.
- 1 Material production with transient expression / bulk pool material (optional)
- 2 Developability assessment
- 3 Go/No-Go decision for cell line development
- 4 Samsung Biologics’ CDMO service (CLD to IND)
Developability Assessment Workflow
-
-
- Material supply
-
-
-
-
Basic Characteristic Analysis
(DSF* & DLS**)
-
-
-
- Heat Stress
Treatment
-
-
-
- Low pH
Treatment
-
-
-
- SEC-HPLE
CE-SDS (NR)
-
-
-
- Data Summarization
& Evaluation
-
*DSF : Differential Scanning Fluorimetry
**DLS : Dynamic Light Scattering
Related Contents
Asymmetrical Structure
Bispecific Antibodies (BsAb) exhibit poor manufacturability and challenging analytics
S-DUAL™ addresses these issues through its unique structure and properties
- The Problem of BsAbs: Mispairings
-
- Standard BsAb - Desired BsAb
- 8 Possible BsAb Combinations - Probability of correct pairing: 1/8
- Mispairings > Poor peak separation > Process & Analytical issues
-
- Similar physiochemical properties of mispaired BsAb result in difficult peak separation
- Challenging purification, analytics and poor productivity
- S-DUAL™: Address BsAb Mispairings
-
S-DUAL™ BsAb Platform Structure
Asymmetric antibody structure, along with knob-and-holes at the CH3 regions, assures that only your desired BsAb is produced without mispairings.
S-DUAL™ platform expresses BsAb from a single cell line, reducing operational complexity.
Correctly Paired bsAb
Impurities are removed with ease through standard purification methods
- SEC-HPLC: Consistent purities in excess of 98%
- Reducing CE-SDS: Main peak is comprised of the expected ratio of LC/HC, demonstrating correct LC/HC pairing of intact BsAb
SEC-HPLC (%)
- S-DUAL
-
- HMW
- Main
- LMW
- (VEGF x HER2)
-
- 0.6
- 98.5
- 0.9
CE-SDS (%)
- S-DUAL
-
- 1H1L
- 2H1L
- Main
- (VEGF x HER2)
-
- 0.8
- 2.6
- 96.6
CE-SDS - After 3-step purification, Correct hetero-dimerization >96%
*CE-SDS : Capillary Electrophoresis Sodium Dodecyl Sulfate
SEC-HPLC - Transient expression, after 3-step purification, Monomer purity >98%
*SEC-HPLC : Size Exclusion-High-Performance Liquid Chromatography
Low Immunogenicity Risk
S-DUALTM consists of components derived from human immunoglobulin
In silico models support the low immunogenicity of BsAb resulting from the S-DUALTM platform
*In silico assessment of Immunogenicity : Performed by Abeza using their iTope™ and T Cell Epitope Database (TCED™) platform